In 2025, GlaxoSmithKline Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, GlaxoSmithKline Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 1,002.89a | 774.32a | 486.95b | |
Total Scope 2 | ||||
Unspecified Calculation Method | 9,419.11a | 9,957.92a | 10,202.75b | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 2.2855a | 1.8697a | 1.2295b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of GlaxoSmithKline Pharmaceuticals amounted to 10,422 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of GlaxoSmithKline Pharmaceuticals decreased by 2.89%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of GlaxoSmithKline Pharmaceuticals were 1,002.89 metric tons of CO₂ equivalent (tCO₂e).a
Since 2023, GlaxoSmithKline Pharmaceuticals's Scope 1 emissions have increased by 105.95%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2024), GlaxoSmithKline Pharmaceuticals's Scope 1 emissions increased by 29.52%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, GlaxoSmithKline Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 9,419.11 tCO₂e without specifying the calculation method.a
Since 2023, GlaxoSmithKline Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that GlaxoSmithKline Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2024), GlaxoSmithKline Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that GlaxoSmithKline Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, GlaxoSmithKline Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a
In 2025, GlaxoSmithKline Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 1,002.89 tCO₂e and total revenues of USD 439 millions. This translates into an emissions intensity of 2.29 tCO₂e per millions USD.a
In 2025, GlaxoSmithKline Pharmaceuticals reported a Scope 1 emissions intensity of 2.29 tCO₂e per millions USD. Compared to the peer group median of 5.25, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, GlaxoSmithKline Pharmaceuticals ranked 3 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places GlaxoSmithKline Pharmaceuticals among the top performers, with one of the lowest emissions intensities relative to peers.a